UPDATE: RBC Capital Starts MannKind (MNKD) at Sector Perform

May 13, 2021 4:12 PM EDT
Get Alerts MNKD Hot Sheet
Price: $4.05 +0.50%

Rating Summary:
    8 Buy, 3 Hold, 6 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 12 | Down: 7 | New: 31
Trade Now! 
Join SI Premium – FREE
(Updated - May 13, 2021 4:14 PM EDT)

RBC Capital analyst Daniel Busby initiates coverage on MannKind (NASDAQ: MNKD) with a Sector Perform rating and a price target of $5.00.

The analyst comments "MNKD’s Technosphere formulation technology allows for differentiated oral inhalation across a range of therapeutic areas. Lead product Afrezza has regained commercial momentum in the sizable mealtime insulin market, while Tyvaso DPI represents a meaningful potential source of future royalty income. Following the stock's ~250% move higher over the last 12 months, we believe both products are largely priced into shares, but pipeline optionality leaves us with an upward bias. We initiate coverage with a Sector Perform rating and $5 price target."

For an analyst ratings summary and ratings history on MannKind click here. For more ratings news on MannKind click here.

Shares of MannKind closed at $4.02 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

RBC Capital